Wedbush upgraded Mersana Therapeutics to Outperform from Neutral with a price target of $7, up from $2.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRSN:
- Bad News for Mersana Therapeutics Stock: This New Risk Has Been Added
- Mersana Therapeutics Shares Corporate Presentation Update
- Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
- Mersana Therapeutics to Present at Upcoming Investor Conferences
- Mersana Therapeutics (MRSN) Q4 Earnings Cheat Sheet